Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto
Lobe Sciences Ltd. (OTCQB: LOBEF), a clinical stage biopharmaceutical company, will participate in the upcoming ArcStone-Kingswood Growth Summit on September 18, 2025 at the St. Regis Toronto. CEO Dr. Frederick D Sancilio will present the company's recent milestones and growth strategy.
The summit will feature over 20 companies and includes pre-arranged 1-on-1 meetings with investors, panel discussions, and networking opportunities. The event provides a platform for investors to connect with industry professionals and stay updated on key developments.
Lobe Sciences Ltd. (OTCQB: LOBEF), una società biofarmaceutica in fase clinica, parteciperà al prossimo ArcStone-Kingswood Growth Summit il 18 settembre 2025 al St. Regis di Toronto. Il CEO Dr. Frederick D Sancilio presenterà i traguardi recenti e la strategia di crescita dell'azienda.
Il summit ospiterà oltre 20 aziende e prevede incontri individuali 1-on-1 con investitori, tavole rotonde e opportunità di networking. L'evento offre una piattaforma per gli investitori per connettersi con professionisti del settore e rimanere aggiornati sugli sviluppi chiave.
Lobe Sciences Ltd. (OTCQB: LOBEF), una empresa biofarmacéutica en fase clínica, participará en la próxima ArcStone-Kingswood Growth Summit el 18 de septiembre de 2025 en el St. Regis de Toronto. El CEO Dr. Frederick D Sancilio presentará los hitos recientes y la estrategia de crecimiento de la empresa.
La cumbre contará con más de 20 compañías y contará con reuniones 1 a 1 preorganizadas con inversores, paneles de discusión y oportunidades de networking. El evento ofrece una plataforma para que los inversores se conecten con profesionales del sector y se mantengan al tanto de los desarrollos clave.
Lobe Sciences Ltd. (OTCQB: LOBEF), 임상 단계의 생물의약품 회사, 다가오는 ArcStone-Kingswood Growth Summit에 2025년 9월 18일 토론토의 St. Regis에서 참석합니다. CEO 프레드릭 D 샌치리오 박사는 회사의 최근 이정표와 성장 전략을 발표합니다.
이번 서밋은 20개 이상의 기업이 참여하고 투자자와의 사전 1:1 미팅, 패널 토론, 네트워킹 기회가 포함됩니다. 이 행사는 투자자들이 업계 전문가들과 연결하고 주요 발전 상황을 파악할 수 있는 플랫폼을 제공합니다.
Lobe Sciences Ltd. (OTCQB: LOBEF), une société biotechnologique en phase clinique, participera au prochain ArcStone-Kingswood Growth Summit le 18 septembre 2025 au St. Regis de Toronto. Le PDG Dr. Frederick D Sancilio présentera les récents jalons et la stratégie de croissance de l'entreprise.
Le sommet réunira plus de 20 entreprises et comprendra des réunions 1 contre 1 préorganisées avec les investisseurs, des tables rondes et des opportunités de réseautage. L'événement offre une plateforme permettant aux investisseurs de se connecter avec des professionnels du secteur et de rester informés des développements clés.
Lobe Sciences Ltd. (OTCQB: LOBEF), ein klinisches biopharmazeutisches Unternehmen, wird am kommenden ArcStone-Kingswood Growth Summit am 18. September 2025 im St. Regis Toronto teilnehmen. CEO Dr. Frederick D Sancilio wird die jüngsten Meilensteine des Unternehmens und seine Wachstumsstrategie vorstellen.
Der Gipfel wird mehr als 20 Unternehmen umfassen und vorab organisierte 1-zu-1-Meetings mit Investoren, Podiumsdiskussionen und Networking-Möglichkeiten beinhalten. Die Veranstaltung bietet Investoren eine Plattform, sich mit Branchenexperten zu vernetzen und über wichtige Entwicklungen auf dem Laufenden zu bleiben.
Lobe Sciences Ltd. (OTCQB: LOBEF)، شركة أبحاث حيوية في مرحلة سريرية، ستشارك في قمة ArcStone-Kingswood Growth Summit القادمة في 18 سبتمبر 2025 في فندق St. Regis تورنتو. سيقدم الرئيس التنفيذي الدكتور فريدريك D سانچيلو أحدث الإنجازات واستراتيجية نمو الشركة.
ستضم القمة أكثر من 20 شركة وتتضمن اجتماعات 1-على-1 مرتبة مسبقاً مع المستثمرين، وجلسات نقاش وفرص للتواصل. يوفر الحدث منصة للمستثمرين للاتصال بمهنيي الصناعة والبقاء على اطلاع بالتطورات الرئيسية.
Lobe Sciences Ltd. (OTCQB: LOBEF)，一家处于临床阶段的生物制药公司，将参加即将于2025年9月18日在多伦多St. Regis举办的 ArcStone-Kingswood Growth Summit。首席执行官 Frederick D Sancilio 博士将介绍公司近期的里程碑和增长策略。
峰会将汇聚超过 20 家企业，并提供与投资者的预设一对一会面、小组讨论和网络交流机会。该活动为投资者提供一个与行业专业人士联系并了解关键进展的平台。
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - September 15, 2025) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming ArcStone-Kingswood Growth Summit in Toronto, taking place at the St. Regis Toronto on September 18, 2025. Dr. Frederick D Sancilio, CEO of Lobe Sciences Ltd, will be presenting the company's recent milestones and future growth strategy.
The ArcStone-Kingswood Growth Summit will be hosting over 20 companies and a curated group of investors for a full day of pre-arranged, targeted 1-on-1 meetings, panel discussions and networking opportunities.
Alongside the schedule of pre-booked meetings matching investors with appropriate projects, the conference program will provide amble opportunities to mix and mingle with the industry professionals and catch up on key industry developments.
Interested investors who would like to attend the ArcStone-Kingswood Growth Summit can register to request for a free invitation here.
About ArcStone Securities and Investments Corp.
ArcStone Securities and Investments Corp. is a diversified financial services firm with offices in Toronto and New York. Our firm specializes in providing bespoke solutions to mid-market companies worldwide, with a particular focus on cross-border transactions between Canada and the United States. Our partnership with Kingswood US enhances our ability to offer a full spectrum of financial services to our clients.
About Kingswood US
Kingswood US is a mid-market investment bank with a strong retail equity capital markets franchise and deep-rooted investment bank. The firm is dedicated to providing comprehensive financial services, including investment banking, wealth management, and capital raising, to clients across the United States.
About Lobe Sciences Ltd.
Lobe Sciences Ltd. is a clinical stage biopharmaceutical company focused on developing novel therapies for rare neurological and hematological conditions. The company operates through two subsidiaries:
Cynaptec Pharmaceuticals, Inc. (a private Delaware company currently owned
64% by Lobe Sciences Ltd) is advancing Conjugated Psilocin (CP), a patented new chemical entity targeting Chronic Cluster Headache, an orphan indication. Substance use disorder (SUD) and possibly additional CNS disorders and other indications are under strategic review.Altemia, Inc. is addressing sickle cell disease with two complementary assets: a medical food currently in early-stage distribution, and S-100, a patent-pending therapeutic candidate designed to treat the underlying pathology of the disease.
Lobe's pipeline is differentiated by intellectual property, clinical momentum, and a strategic focus on high-value, underserved markets.
For additional Information, please contact:
Lobe Sciences Ltd.
info@lobesciences.com
www.lobesciences.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265683
FAQ
When and where is Lobe Sciences (LOBEF) presenting at the ArcStone-Kingswood Growth Summit 2025?
Who will be presenting for Lobe Sciences (LOBEF) at the Growth Summit?
What type of company is Lobe Sciences (LOBEF)?
How can investors attend the ArcStone-Kingswood Growth Summit featuring Lobe Sciences?
